Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 10/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL693275 | 1.00 | PRCP (0.49) | PRCPKCNH2HPGDSOPRM1OPRD1 | |
| SCHEMBL692436 | 0.93 | PRCP (0.49) | PRCPKCNH2OPRM1OPRD1CYP3A4 | |
| SCHEMBL692368 | 0.91 | PRCP (0.51) | PRCPKCNH2HPGDSOPRM1OPRD1 | |
| SCHEMBL693276 | 0.91 | PRCP (0.51) | PRCPKCNH2HPGDSOPRM1OPRD1 | |
| SCHEMBL3240920 | 0.89 | KCNH2 (0.49) | PRCPKCNH2HPGDSOPRM1OPRD1 | |
| SCHEMBL3238733 | 0.89 | KCNH2 (0.49) | PRCPKCNH2HPGDSOPRM1OPRD1 | |
| SCHEMBL690591 | 0.88 | KCNH2 (0.53) | PRCPKCNH2HPGDSOPRM1OPRD1 | |
| SCHEMBL690905 | 0.88 | KCNH2 (0.53) | PRCPKCNH2HPGDSOPRM1OPRD1 | |
| SCHEMBL2961147 | 0.88 | KCNH2 (0.46) | PRCPKCNH2HPGDSOPRM1OPRD1 | |
| SCHEMBL2956271 | 0.88 | KCNH2 (0.46) | PRCPKCNH2HPGDSOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049116-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-02-29 | — | — | EP | claimed |